PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.

Calquence is also being evaluated as a potential 1st-line treatment for patients with MCL, in combination with bendamustine and rituximab in the Phase 3 ACE-LY-308 clinical trial, which has an ...

Calquence is also in trials for a range of B-cell malignancies and other cancers including chronic lymphocytic leukaemia (CLL), MCL, Waldenström macroglobulinaemia (WM), follicular lymphoma ...

After years off medication, I finally enjoyed a grapefruit cocktail — symbolizing freedom from cancer’s constant shadow and hope for the future.

The pharmaceutical industry’s lobbying muscle scored a high-stakes victory on Monday when the Senate parliamentarian reversed a previous decision and ruled that the Optimizing Research Progress Hope ...

Recent oncology breakthroughs showcase innovative treatments and approvals, enhancing patient outcomes in CLL, RCC, NSCLC, ...

See the latest AstraZeneca PLC ADR stock price (AZN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

The provision, part of the Senate budget bill, was described as “a blatant giveaway to the pharmaceutical industry that would keep drug prices high for patients while draining $5 billion in taxpayer ...